Supplementary Methods, Tables 1 - 3, Figures 1 - 7 from HDAC Inhibitors Augmented Cell Migration and Metastasis Through Induction of PKCs Leading to Identification of Low Toxicity Modalities for Combination Cancer Therapy

PDF file, 2015K, Table S1. MMPs and PKCs primer pairs and PCR conditions for RT-PCR. Table S2. MMPs and PKCs primer pairs and PCR conditions for ChIP assay. Table S3. Antibodies for Western blot analysis. Figure S1. The remaining subset of human cancer cell lines without enhancement of cell migration activity after TSA treatment. Figure S2. Validation of HDACi-enhanced cell migration with treatments of 6 different HDACi. Figure S3. HDACi treatments of HCC and lung cancer cells enhance in vivo experimental metastasis. Figure S4. Treatment of HDACi modulated MMPs and PKCs expressions. Figure S5. The combination treatments of HDACi with MMPi or PKCi repress HDACi-enhanced migration activity. Figure S6. The effects of HDACi and PKCi on tumorigenesis, toxicity and tumor-progressive protein expressions in vivo. Figure S7. Suppressive effects of tumorigenesis and metastasis in liver metastasis model of TSA/Tam and TSA/Cur treated mice.